Skip to main content
Close
Home
Society of Hospital Medicine
Presented by Society of Hospital Medicine
Home
Twitter Facebook LinkedIn Instagram YouTube Hospital Medicine Exchange Email RSS Feed

Andrew D. Bowser

News

Phase 2 studies show potential of FcRn blockade in primary ITP

Author:
Andrew D. Bowser
Publish date: December 12, 2019

ORLANDO – The results support continued investigation in phase 3 trial for rozanolixizumab and efgartigimod, according to investigators.

  • Read More

News

New ASH guideline: VTE prophylaxis after major surgery

Author:
Andrew D. Bowser
Publish date: December 12, 2019

ORLANDO – The chair of VTE guidelines panel presented highlights of the latest guidelines in a special session at the annual meeting of the...

  • Read More

News

Fibrosis scoring systems have ‘modest’ predictive value in general population

Author:
Andrew D. Bowser
Publish date: December 10, 2019

For predicting severe liver disease, investigators say today’s scoring systems lack precision in unselected populations with low prevalence of...

  • Read More

News

Efficacy of postvenetoclax therapy may depend on prior agent exposure in CLL

Author:
Andrew D. Bowser
Publish date: December 10, 2019

ORLANDO – The multicenter study was aimed at addressing the knowledge gap around what therapy to use after venetoclax.

  • Read More

News

Fragmentation of sickle cell disease care starts in young adulthood

Author:
Andrew D. Bowser
Publish date: December 8, 2019

ORLANDO – Imagine what that would be like to have a chronic, debilitating illness and to have to go to multiple different hospitals, during this...

  • Read More

News

Kidney function in African American AML patients not linked to reduced survival compared with whites

Author:
Andrew D. Bowser
Publish date: December 7, 2019

ORLANDO – Liberalizing renal function eligibility criteria might promote recruitment of African Americans to AML...

  • Read More

News

Bispecific CAR T-cells yield high response rate in relapsed/refractory myeloma

Author:
Andrew D. Bowser
Publish date: December 7, 2019

ORLANDO – Duration of response, manageable safety support further investigation of dual-targeted strategy, according to investigator.

  • Read More

News

UC: Tofacitinib tied to modest, reversible lipid increases, infrequent CV events

Author:
Andrew D. Bowser
Publish date: December 6, 2019

The observation period was still relatively short, however so longer-term data may be needed to more fully characterize lipid impact and...

  • Read More

News

No clear-cut evidence of vedolizumab effect in retrospective study of primary sclerosing cholangitis

Author:
Andrew D. Bowser
Publish date: December 6, 2019

Cholestasis markers dropped in some, but not all, patients with primary sclerosing cholangitis and inflammatory bowel disease, though a...

  • Read More

News

Early colonoscopy for acute lower GI bleeding fails to improve diagnostic yield or reduce rebleeding rate

Author:
Andrew D. Bowser
Publish date: December 3, 2019

Compared with elective colonoscopy, recommended procedure resulted in no statistical difference in primary or key secondary outcome.

  • Read More

News

What’s new in hepatitis C: Four themes that dominated at the Liver Meeting

Author:
Andrew D. Bowser
Publish date: November 22, 2019

BOSTON – AASLD highlights included treatment of persons who inject drugs, new directions in pangenotypic therapy,...

  • Read More

News

Skin barrier dysfunction mutations vary by race, disease persistence in children with AD

Author:
Andrew D. Bowser
Publish date: November 21, 2019

Findings may have implications for genetic test development, investigators note.

  • Read More

News

AASLD debrief: Five drugs show promise in NAFLD (and two do not)

Author:
Andrew D. Bowser
Publish date: November 21, 2019

BOSTON – Promising new data for cotadutide, licogliflozin, tropifexor, saroglitazar, and PF-05221304 highlighted in...

  • Read More

News

TARGET-NASH: One-third of NAFLD, NASH patients lost weight, but not all kept it off

Author:
Andrew D. Bowser
Publish date: November 20, 2019

BOSTON – With no approved pharmacologic treatments for NAFLD and NASH, weight reduction remains one of the mainstays of treatment.

  • Read More

News

Ask about vaping in patients with respiratory symptoms, CDC says

Author:
Andrew D. Bowser
Publish date: November 20, 2019

New CDC recommendations intended to help HCPs pinpoint and manage vaping-associated lung injuries as seasonal respiratory infections trend upward...

  • Read More

Pages

  • « first
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • last »
An Official Publication of the Society of Hospital Medicine

Society of Hospital Medicine
Twitter Facebook LinkedIn Instagram YouTube Hospital Medicine Exchange Email RSS Feed

Copyright  © 2023 Frontline Medical Communications Inc., Newark, NJ, USA. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

Menu Close